(Q37627196)

21 August 2017

1 reference

title

New oral anticoagulants: a practical guide for clinicians (English)

1 reference

21 August 2017

1 reference

1 reference

Ann K Wittkowsky

1

1 reference

21 August 2017

publication date

1 February 2010

1 reference

Journal of Thrombosis and Thrombolysis

21 August 2017

published in

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

182-191

1 reference

https://scigraph.springernature.com/pub.10.1007/s11239-009-0409-0

21 August 2017

exact match

0 references

cites work

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

1 reference

12 December 2020

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

1 reference

12 December 2020

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

1 reference

12 December 2020

Factor Xa or thrombin: is thrombin a better target?

1 reference

12 December 2020

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

1 reference

12 December 2020

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

12 December 2020

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

12 December 2020

New anticoagulants: anti IIa vs anti Xa--is one better?

1 reference

12 December 2020

The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions

1 reference

12 December 2020

Apixaban metabolism and pharmacokinetics after oral administration to humans

1 reference

12 December 2020

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

1 reference

12 December 2020

Factor Xa or thrombin: is factor Xa a better target?

1 reference

12 December 2020

Functional interaction of intestinal CYP3A4 and P-glycoprotein

1 reference

12 December 2020

Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.

1 reference

12 December 2020

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

12 December 2020

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

12 December 2020

Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?

1 reference

12 December 2020

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

1 reference

12 December 2020

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

1 reference

12 December 2020

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

12 December 2020

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

12 December 2020

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

12 December 2020

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

1 reference

12 December 2020

10.1007/S11239-009-0409-0

Identifiers

DOI

1 reference

21 August 2017

1 reference